ACRS at a glance
Aclaris Therapeutics, Inc. (ACRS, SEC CIK 1557746) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as August 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Aclaris Therapeutics, Inc. (ACRS) reported revenue of $7.8 million (down 58.2% from FY2024) and a net loss of $64.9 million. Diluted EPS was -$0.53.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Aclaris Therapeutics, Inc. (ACRS) shares worth $154.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $7.8M
- −58.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $154.5M · −1 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 7.01 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $1.481M, down $1.818M YoY from $3.299M, primarily lower licensing revenue
- Q3 net loss $18.510M vs $14.614M YoY, operating loss $21.344M vs $17.149M
- Strongest R&D growth: ATI-052 expense $5.906M, up $4.069M YoY; ATI-9494 $4.676M, up $3.272M
- Cash and securities $204.6M, including $20.4M cash and $184.2M marketable securities
- Nine-month operating cash use $62.076M vs $33.982M; management expects losses and additional capital needs near term
Risk Factors
- Liquidity risk: $204.6 million cash, cash equivalents and marketable securities against $59.8 million nine-month net loss
- Financing risk: October offering added $46.7 million net proceeds through 7,785,714 shares and 6,500,000 pre-funded warrants
- Marketable-securities concentration: $184.2 million fair value, including $70.5 million corporate debt securities maturing within one to three years
- Regulatory milestone exposure: $10.7 million contingent consideration tied to Confluence regulatory and commercial milestones
AI summary of the ACRS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Phase 2 ADMIRATION top-line results announced for bosakitug in moderate-to-severe atopic dermatitis
- Results could determine bosakitug’s development path and competitive positioning in atopic dermatitis
Item 8.01: Other Events
- Bosakitug Phase 2 missed its Week 24 primary endpoint and secondary endpoints, materially weakening its eczema development outlook
- Robust TSLP target engagement and immune biomarker downregulation did not translate into clinical efficacy
Item EX-99.1: Item EX-99.1
- Phase 2 ADMIRATION trial failed primary and secondary endpoints in moderate-to-severe atopic dermatitis
- Bosakitug showed robust TSLP target engagement but no demonstrated clinical efficacy, weakening its standalone AD opportunity
Item EX-99.2: Item EX-99.2
- Phase 2b A LP HA trial initiated for modzatinib in moderate-to-severe lichen planus, expanding the lead asset into a disease with no FDA-approved targeted therapies
- Approximately 100 participants across oral erosive, cutaneous and lichen planopilaris cohorts, with two dose levels versus placebo
Item EX-99.1: Item EX-99.1
- Q3 revenue $1.5M versus $3.3M, while net loss widened to $18.5M from $14.6M
- Cash, equivalents and marketable securities $204.6M, with October financing adding $50.0M gross proceeds
Item 2.02: Results of Operations and Financial Condition
- Press release covers Aclaris financial results for the quarter ended September 30, 2026
- Nine-month results through September 30, 2026 also announced
Item EX-99.1: Item EX-99.1
- Phase 1b proof-of-concept success for ATI-052 in AD and asthma, materially validating dual TSLP/IL-4Rα targeting
- AD trial: 14 patients, 45% placebo-adjusted EASI improvement and 43% placebo-adjusted itch improvement at day 57
Item 8.01: Other Events
- Preliminary cash, equivalents and marketable securities of $204.6M at September 30, 2026, supporting continued development but subject to material adjustment
- ATI-052 showed 45% placebo-adjusted EASI improvement at day 57 in 14-patient atopic dermatitis trial
Item EX-99.2: Item EX-99.2
- Phase 1b proof-of-concept achieved in atopic dermatitis and asthma, supporting ATI-052 advancement to Phase 2
- Atopic dermatitis: 58% EASI reduction and 78% EASI-50 response versus 13% and 0% placebo at Day 57
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 points investors to Item 8.01 for Aclaris’ cash, cash equivalents and marketable securities as of September 30, 2026
- Liquidity disclosure is the filing’s only financial update, relevant to funding capacity and near-term operations
Item 7.01: Regulation FD Disclosure
- ATI-052 Phase 1b proof-of-concept primary analysis results announced in atopic dermatitis and asthma
- Anti-TSLP/IL-4Rα bispecific antibody data marks an early clinical validation milestone for Aclaris’ pipeline
AI summaries of ACRS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ACRS
Don't miss the next ACRS filing
- Alerts as it files. A push when ACRS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ACRS, by share count.
- Ask anything. An AI agent that reads every ACRS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kolbeck Roland Wilhelm | M | Aug 1, 2026 | 36,375 | - |
| Kolbeck Roland Wilhelm | F | Aug 1, 2026 | 12,385 | $5.20 |
| Kolbeck Roland Wilhelm | M | Aug 1, 2026 | 36,375 | - |
| GOWEN MAXINE | M | Jun 5, 2026 | 11,580 | - |
| SCHIFF ANDREW N | M | Jun 5, 2026 | 11,580 | - |
| Mehra Anand | M | Jun 5, 2026 | 11,580 | - |
| Humphries William D. | M | Jun 5, 2026 | 11,580 | - |
| MILANO VINCENT | M | Jun 5, 2026 | 11,580 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $18.7M | $7.8M |
| Operating Income | - | -$141.9M | -$76.4M |
| Net Income | -$88.5M | -$132.1M | -$64.9M |
| Op. Margin | - | -758.2% | -975.9% |
| Net Margin | - | -705.5% | -829.6% |
| Balance Sheet | |||
| Total Assets | $197.4M | $220.3M | $160.5M |
| Equity | - | $155.6M | $103.1M |
| ROE | - | -84.9% | -63.0% |
| Per Share | |||
| EPS | $-1.27 | $-1.71 | $-0.53 |
| Cash Flow | |||
| Operating CF | - | -$20.1M | -$47.1M |
| CapEx | $1.3M | $121K | $111K |
Source: XBRL data in Aclaris Therapeutics, Inc. (ACRS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ACRS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $154.5M |
| Q2 2026 | 27 | $152.1M |
| Q1 2026 | 26 | $102.4M |
| Q4 2025 | 24 | $87.6M |
| Q3 2025 | 24 | $57.7M |
| Q2 2025 | 22 | $42.4M |
| Q1 2025 | 19 | $31.3M |
| Q4 2024 | 14 | $31.6M |
- Goldman Sachs Group+584.8K (+96%)
- Invesco Ltd+569.5K (+234%)
- State Street Corp+440.8K (+14%)
- BlackRock+339.6K (+3%)
- Morgan Stanley+112.0K (+83%)
- Renaissance Technologies LLC−734.7K (-90%)
- Millennium Management−473.2K (-90%)
- Wells Fargo & Co−72.7K (-67%)
- Vanguard Portfolio Management LLC−43.8K (-3%)
- Citigroup−37.7K (-32%)
- Franklin Resources+871.0K
- Principal Financial Group+13.0K
- D.E. Shaw & Co−414.5K
- FMR LLC (Fidelity)−313.9K
- Mangrove Partners−50.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 182 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ACRS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 27, 2026 | - | Analysis | - |
| 8-K | Oct 27, 2026 | - | Analysis | - |
| SC 13G | Sep 21, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 4 | May 5, 2026 | - | - | - |
| 8-K | Apr 28, 2026 | - | Analysis | - |
| 4 | Apr 27, 2026 | - | - | - |
| SC 13G | Apr 7, 2026 | - | - | |
| SC 13G | Mar 17, 2026 | - | - | |
| 8-K | Mar 11, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
ACRS SEC filings: frequently asked questions
Which institutions hold ACRS stock?
As of September 30, 2026, the largest Aclaris Therapeutics, Inc. (ACRS) holders among the 13F filers tracked by SignalX were BlackRock ($54.6 million), Vanguard Capital Management LLC ($30.8 million), State Street Corp ($19.4 million), Citadel Advisors LLC ($9.3 million), Vanguard Portfolio Management LLC ($7.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ACRS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Aclaris Therapeutics, Inc. (ACRS) reported revenue of $7.8 million (down 58.2% from FY2024) and a net loss of $64.9 million. Diluted EPS was -$0.53. The figures come from the XBRL data in the 10-K.
What did ACRS report in its latest 8-K?
Aclaris Therapeutics, Inc. (ACRS) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Phase 2 ADMIRATION top-line results announced for bosakitug in moderate-to-severe atopic dermatitis.
What are the latest ACRS SEC filings?
Aclaris Therapeutics, Inc. (ACRS) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on August 4, 2026.
What is ACRS's SEC CIK number?
Aclaris Therapeutics, Inc. (ACRS)'s SEC Central Index Key (CIK) is 1557746. EDGAR lists every ACRS filing under that number.
Ask anything about ACRS
The research agent reads ACRS's filings, financials, insider trades and 13F holders, then answers with sources.